Cowen set a $55.00 price objective on Revance Therapeutics (NASDAQ:RVNC) in a report issued on Wednesday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other brokerages also recently commented on RVNC. Zacks Investment Research upgraded Revance Therapeutics from a hold rating to a buy rating and set a $28.00 target price for the company in a research note on Tuesday, September 19th. Cantor Fitzgerald restated a buy rating and issued a $50.00 target price on shares of Revance Therapeutics in a research note on Tuesday, September 26th. Piper Jaffray Companies restated a buy rating and issued a $28.00 target price on shares of Revance Therapeutics in a research note on Friday, October 27th. Mizuho assumed coverage on Revance Therapeutics in a research note on Thursday, November 16th. They issued a buy rating and a $37.00 target price for the company. Finally, Barclays assumed coverage on Revance Therapeutics in a research note on Monday, November 27th. They issued an overweight rating and a $31.00 target price for the company. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $44.30.

Revance Therapeutics (RVNC) traded up $0.20 during trading hours on Wednesday, reaching $33.95. The company had a trading volume of 284,012 shares, compared to its average volume of 337,378. The firm has a market capitalization of $1,214.53, a P/E ratio of -8.93 and a beta of 1.62. Revance Therapeutics has a fifty-two week low of $18.00 and a fifty-two week high of $37.45.

Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.01) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.95) by ($0.06). The firm had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.05 million. Revance Therapeutics had a negative return on equity of 67.85% and a negative net margin of 37,161.00%. The firm’s revenue for the quarter was up .0% on a year-over-year basis. During the same quarter last year, the business posted ($0.64) earnings per share. analysts predict that Revance Therapeutics will post -3.74 earnings per share for the current year.

In other news, CEO L Daniel Browne sold 7,600 shares of Revance Therapeutics stock in a transaction that occurred on Wednesday, November 22nd. The stock was sold at an average price of $24.94, for a total transaction of $189,544.00. Following the sale, the chief executive officer now owns 133,188 shares of the company’s stock, valued at $3,321,708.72. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Mark J. Foley purchased 20,000 shares of the business’s stock in a transaction dated Tuesday, November 7th. The shares were acquired at an average cost of $26.96 per share, for a total transaction of $539,200.00. Following the acquisition, the director now owns 6,000 shares of the company’s stock, valued at approximately $161,760. The disclosure for this purchase can be found here. Insiders own 18.86% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in RVNC. PointState Capital LP raised its holdings in shares of Revance Therapeutics by 58.5% during the second quarter. PointState Capital LP now owns 438,200 shares of the biopharmaceutical company’s stock valued at $11,568,000 after buying an additional 161,700 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Revance Therapeutics by 7.3% during the second quarter. Vanguard Group Inc. now owns 931,623 shares of the biopharmaceutical company’s stock valued at $24,595,000 after buying an additional 63,505 shares during the last quarter. QS Investors LLC bought a new stake in shares of Revance Therapeutics during the second quarter valued at approximately $1,564,000. Northern Trust Corp raised its holdings in shares of Revance Therapeutics by 19.9% during the second quarter. Northern Trust Corp now owns 318,877 shares of the biopharmaceutical company’s stock valued at $8,418,000 after buying an additional 52,940 shares during the last quarter. Finally, Pura Vida Investments LLC bought a new stake in shares of Revance Therapeutics during the third quarter valued at approximately $1,378,000. 76.69% of the stock is currently owned by institutional investors.

WARNING: This piece of content was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://www.watchlistnews.com/cowen-reiterates-55-00-price-target-for-revance-therapeutics-rvnc/1817091.html.

About Revance Therapeutics

Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.

Analyst Recommendations for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.